Govt-Led Innovation Support In Focus As Shanghai Biopharma Sector Rebounds
Sights On Novel Assets
Shanghai’s biopharma sector has started to regain momentum and is beginning to see its innovation bets paying off, with support from the local government.
You may also be interested in...
Plus deals involving Kelun Biotech, Pierre Fabre/Vertical, Novo Nordisk/Broad Institute, ABL Bio/Synaffix, Kriya/Tramontane, Palisade/Giiant and more.
A Chinese court decision sheds light on how Chinese major Hengrui Medicine is seeking to reduce or avoid potential losses worth up to $27m following regulatory setbacks with the tubulin inhibitor plinabulin, in-licensed from BeyondSpring in 2021.
Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.